Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medichem’s Stampa Takes Lead At Medicines For Europe

Elisabeth Stampa Sets Out Priorities As She Takes Over Presidency From Rebecca Guntern

Executive Summary

Medichem CEO Elisabeth Stampa has been named as the new president of Medicines for Europe, setting out policy priorities that include bolstering the European API sector and supporting a “green transformation” for manufacturing.

You may also be interested in...



Medicines For Europe Urges Inclusion Of Essential Medicines In Industrial Policy Plans

Medicines for Europe has called for the EU’s IPCEI on health to encourage access to manufacturing incentives for APIs and off-patent medicines, which so far have been left out of the initiative.

Generics Industry Takes Action To Maintain Access In Ukraine

Efforts are being made across the European off-patent community to bolster the supply chain and ensure access to medicines in Ukraine, industry association Medicines for Europe tells Generics Bulletin. It has urged the EU to take a leading role in coordinating supplies through the HERA emergency response body.

German Tamoxifen Shortage Shows Consequences Of Cost Containment

Supply issues around breast cancer treatment tamoxifen in Germany demonstrate the damaging effects of European cost-containment measures, Medicines for Europe has warned, citing an “urgent need to revise unsustainable pricing and tendering policies.”

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB151708

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel